



Docket No. 17008 DIV5CON3(AP) IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Burk

Serial No: 10/087,867

Conf. No. 9687

Filed: February 28, 2002

CYCLOPENTANE(ENE) HEPTENOIC OR HEPTANOIC ACIDS AND DERIVATIVES THEREOF USEFUL AS THERAPEUTIC AGENTS

Commissioner for Patents Alexandria, VA 22313-1450 RECEIVED

Group No.: 1626

JUN 1 2 2003

TECH CENTER 1600/2900

Examiner: Robert Gerstl

TECH CENTER 1600/2900

7NN I \$ 5003

BECEINED

REPLY

Dear Sir:

In response to the Advisory Action dated mailed May 29, 2003, enclosed is the corrected Terminal Disclaimer.

Respectfully Submitted,

Assistant General Counsel

ALLERGAN, INC. Legal Department (T2-7H) 2525 Dupont Drive Irvine, CA 92612 Direct: 714-246-4669

Fax: 714-246-4249

CERTIFICATE OF MAILING

I HEREBY GERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST-CLASS MAIL IN AN

ENVELOPE ADDRESSED TO:

JUN 1 0 2003 JUNION TO THE THE PARTY OF THE

Docket No. 17008 DIV5CON3(AP) IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

In Re Application of:

Burk

Serial No: 10/087,867

Conf. No. 9687

Filed: February 28, 2002

For: CYCLOPENTANE(ENE)
HEPTENOIC OR HEPTANOIC ACIDS
AND DERIVATIVES THEREOF USEFUL
AS THERAPEUTIC AGENTS

Commissioner for Patents Alexandria, VA 22313-1450 Group No.: 1626

Examiner: Robert Gerstl

RECEIVED

JUN 1 2 2003

TECH CENTER 1600/2900

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A PRIOR PATENT

Dear Sir:

The owner, Allergan of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 USC 154 and 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6,414,022. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent is commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 USC 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held

unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminal disclaimed under 37 CFR 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

The undersigned is an attorney of record.

Date:

By:

ROBERT J. BARAN

Assistant General Counsel

6/4/03 } Baran

ALLERGAN, INC.

- X Please charge the terminal disclaimer fee under 37 CFR 1.20(d) to Account No. 01-0885. A duplicate of this terminal disclaimer is enclosed.
- X PTO suggested wording for terminal disclaimer was unchanged.

Please direct all correspondence to:

Robert J. Baran (T2-7H) Attorney of Record ALLERGAN, INC. 2525 Dupont Drive Irvine, CA 92612

Telephone: 714/246-4669 Telecopier: 714/246-4249